Remifentanil Hydrochloride Injection

What This Remifentanil Shortage Record Means

The FDA Drug Shortages database lists this record for Remifentanil Hydrochloride Injection (brand: REMIFENTANIL HYDROCHLORIDE) from Fresenius Kabi USA, LLC with a current status of Active Shortage. The affected dosage form is Injection, presented as Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03). Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Jun 28, 2022 and was last updated Feb 25, 2026. The FDA cites the following reason: Next release March 2026. There are 6 other current records in this database covering the same generic, which gives a fuller picture of how disruption is playing out across manufacturers and dosage forms.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.